SGLT2i Dapagliflozin in primary prevention of chemotherapy induced cardiotoxicity in breast cancer patients treated with neo-adjuvant anthracycline-based chemotherapy +/- trastuzumab: rationale and design of the multicenter PROTECT trial
2025 · Cardio-Oncology · 2 citations
https://doi.org/10.1186/s40959-025-00368-9